3:
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO.
Clin Cancer Res. 2008 Apr 1;14(7):2095-101.
PMID: 18381950 [PubMed - indexed for MEDLINE]
Related Articles
5:
Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study".
Chambers MS, Fleming TJ, Toth BB, Lemon JC, Craven TE, Bouwsma OJ, Garden AS, Espeland MA, Keene HJ, Martin JW, Sipos T.
Oral Oncol. 2007 Jan;43(1):98-105.
PMID: 18027401 [PubMed - indexed for MEDLINE]
Related Articles
6:
Gene expression profiling to predict outcome after chemoradiation in head and neck cancer.
Pramana J, Van den Brekel MW, van Velthuysen ML, Wessels LF, Nuyten DS, Hofland I, Atsma D, Pimentel N, Hoebers FJ, Rasch CR, Begg AC.
Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1544-52. Epub 2007 Oct 10.
PMID: 17931799 [PubMed - indexed for MEDLINE]
Related Articles